Please login to the form below

Not currently logged in


This page shows the latest Tavneos news and features for those working in and with pharma, biotech and healthcare.

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen completes acquisition of ChemoCentryx in deal worth $3.7bn

Amgen gains access to the biopharma’s autoimmune disease treatment Tavneos. Amgen has successfully completed its previously announced acquisition of ChemoCentryx in an agreement valued at approximately $3.7bn in cash. ... In addition to Tavneos, the

Latest news

  • Amgen to acquire ChemoCentryx in $3.7bn cash deal Amgen to acquire ChemoCentryx in $3.7bn cash deal

    The agreement, which includes the acquisition of ChemoCentryx’s autoimmune disease treatment Tavneos (avacopan), will see Amgen pay $52 in cash per share. ... As well as Tavneos, ChemoCentryx has three early-stage drug candidates that target

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts


Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...